Sexton Riley LLP Represents Janssen in Worldwide Collaboration Agreement with Fate Therapeutics for Novel iPSC-derived Cell-based Cancer Immunotherapies
April 2020
Sexton Riley LLP represented Janssen Biotech, Inc., an affiliate of Johnson & Johnson, in its global collaboration and option agreement with Fate Therapeutics, Inc., to research and develop new iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates for the treatment of hematologic malignancies and solid tumors.
Fate Therapeutics' press release is here.